Correspondence on ‘SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease‘

Abstract

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Response to: ‘Correspondence on ‘SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease’’ by C et al

“…1 One patient developed anti-spike but not anti-nucleocapsid antibodies; although the duration of rituximab treatment is not provided, this patient did have circulating CD19+ B cells near the time of infection. 1 In our study, three patients were exposed to rituximab prior to COVID-19. 2 Two of these patients had been treated with rituximab for many years and had undetectable circulating CD19+ B cells, and these patients had negative or variable antibody responses to SARS-CoV-2.…”

“…Shanoj et al describe anti-spike and anti-nucleocapsid antibody test results among five patients with PCR-confirmed COVID-19 and prior exposure to rituximab. 1 Among these patients, one patient developed neither anti-spike nor anti-nucleocapsid antibodies. 1 This patient had been treated with rituximab for several years and had no detectable CD19+ B cells shortly before the onset of COVID-19.…”

“…1 Among these patients, one patient developed neither anti-spike nor anti-nucleocapsid antibodies. 1 This patient had been treated with rituximab for several years and had no detectable CD19+ B cells shortly before the onset of COVID-19. 1 One patient developed anti-spike but not anti-nucleocapsid antibodies; although the duration of rituximab treatment is not provided, this patient did have circulating CD19+ B cells near the time of infection.…”

“…Response to: 'Correspondence on 'SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease'' by Shanoj et al We appreciate the comments by Shanoj et al 1 in response to our letter regarding the SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease. 2 Examining whether patients treated with CD20 inhibitors have antibody responses to SARS-CoV-2 is a question of great clinical importance in the management and vaccination of patients taking these medications during the COVID-19 pandemic.…”

“…1 This patient had been treated with rituximab for several years and had no detectable CD19+ B cells shortly before the onset of COVID-19. 1 One patient developed anti-spike but not anti-nucleocapsid antibodies; although the duration of rituximab treatment is not provided, this patient did have circulating CD19+ B cells near the time of infection. 1 In our study, three patients were exposed to rituximab prior to COVID-19.…”